Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia (Advances in Therapy, (2022), 39, 4, (1474-1488), 10.1007/s12325-021-01948-8)

Valeria Santini, Michael Lübbert, Agnieszka Wierzbowska, Gert J. Ossenkoppele

Research output: Contribution to JournalComment / Letter to the editorAcademic

Abstract

In the original article, a few errors have been identified and subsequently rectified. In the abstract the incorrect phrase ‘‘and limiting the transcription of tumor suppressor genes, leading to gene silencing’’ has now been corrected to ‘‘and leading amongst others to reexpression of silenced tumor suppressor genes.’’ In the key summary points, it has been specified that decitabine is indicated in the European Union (EU). In Table 2 data are erroneous due to a misprint. Total TC for anemia has now been corrected from (925) to (25), total TC for febrile neutropenia has been amended from (922) to (22), and total TC for Pyexia has been amended from (200) to (8). Further updates have been made to improve clarity of sentences but no amendment to the scientific content was made. The original article has been corrected.
Original languageEnglish
Pages (from-to)1489
Number of pages1
JournalAdvances in Therapy
Volume39
Issue number4
Early online date2022
DOIs
Publication statusPublished - Apr 2022

Cite this